Shopping Cart
- Remove All
- Your shopping cart is currently empty
Atecegatran Metoxil (Atecegatran Fexenetil ,AZD0837) is an oral direct thrombin inhibitor,which currently in clinical development for the prevention of stroke and systemic embolic events in patients with atrial fibrillation. AZD0837 is a selective and reversible direct thrombin inhibitor and is a bioconverted to AR-H067637.AZD0837 is well tolerated in healthy male subjects at a single oral dose (15-750 mg) and demonstrated favorable PK properties and reproducible effects on in vitro coagulation time variables, supporting further clinical development.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,820 | 8-10 weeks | |
50 mg | $2,380 | 8-10 weeks | |
100 mg | $3,100 | 8-10 weeks |
Description | Atecegatran Metoxil (Atecegatran Fexenetil ,AZD0837) is an oral direct thrombin inhibitor,which currently in clinical development for the prevention of stroke and systemic embolic events in patients with atrial fibrillation. AZD0837 is a selective and re |
Alias | AZD-0837, AZD0837, AZD 0837, Atecegatran fexenetil |
Molecular Weight | 496.89 |
Formula | C22H23ClF2N4O5 |
Cas No. | 433937-93-0 |
Relative Density. | 1.31g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.